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Abstract
Background: Arginine vasopressin (AVP), a neuropeptide hormone that functions in the regulation of water
homeostasis by controlling water re-absorption at kidneys, is synthesised in supraoptic nucleus and paraventricular
nucleus of the hypothalamus. An increase in plasma osmolality stimulates secretion of AVP to blood circulation and
induces AVP synthesis in these nuclei. Although studies on mechanism of AVP transcriptional regulation in
hypothalamus proposed that cAMP and glucocorticoids positively and negatively regulate Avp expression,
respectively, the molecular mechanisms have remained elusive. Recently, we identified CREB3L1 (cAMP-responsive
element binding protein 3 like 1) as a putative transcription factor of Avp transcription in the rat hypothalamus.
However the mechanism of how CREB3L1 is regulated in response of hyperosmotic stress in the neurons of
hypothalamus has never been reported. This study aims to investigate effect of previously reported regulators
(cAMP and glucocorticoid) of Avp transcription on transcription factor CREB3L1 in order to establish a molecular
explanation for cAMP and glucocorticoids effect on AVP expression.
Results: The effect of cAMP and glucocorticoid treatment on Creb3l1 was investigated in both AtT20 cells and
hypothalamic organotypic cultures. The expression of Creb3l1 was increased in both mRNA and protein level by
treatment with forskolin, which raises intracellular cAMP levels. Activation of cAMP by forskolin also increased Avp
promoter activity in AtT20 cells and this effect was blunted by shRNA mediated silencing of Creb3l1. The forskolin
induced increase in Creb3l1 expression was diminished by combined treatment with dexamethasone, and, in vivo,
intraperitoneal dexamethasone injection blunted the increase in Creb3l1 and Avp expression induced by
hyperosmotic stress.
Conclusion: Here we shows that cAMP and glucocorticoid positively and negatively regulate Creb3l1 expression in
the rat hypothalamus, respectively, and regulation of cAMP on AVP expression is mediated through CREB3L1. This
data provides the connection between CREB3L1, a newly identified transcription factor of AVP expression, with the
previously proposed mechanism of Avp transcription which extends our understanding in transcription regulation
of Avp in the hypothalamus.
Keywords: Transcription, Forskolin, Dexamethasone, Hyperosmotic, Magnocellular neuron, Supraoptic nucleus,
Paraventricular nucleus, AtT20, Rat, Organotypic culture
* Correspondence: mingkwan.greenwood@bristol.ac.uk
1School of Clinical Sciences, University of Bristol, Dorothy Hodgkin Building,
Whitson Street, Bristol BS1 3NY, England
Full list of author information is available at the end of the article
© 2015 Greenwood et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Greenwood et al. Molecular Brain  (2015) 8:68 
DOI 10.1186/s13041-015-0159-1
Background
Expression of the gene encoding the neuropeptide hor-
mone arginine vasopressin (AVP), which functions in
water homeostasis, is found in the magnocellular neurons
(MCNs) of supraoptic nucleus (SON) and paraventricular
nucleus (PVN). The AVP prohormone is synthesised in
the cell body and subsequently transported to the axon
terminal in the posterior pituitary where it is stored [1].
Secretion is activated by hyperosmotic conditions through
excitatory inputs from circumventricular organs [2, 3]. An
increase of plasma osmolality activates secretion of AVP
into the blood circulation to control water re-absorption
at the kidney [4].
Whilst the regulation of Avp gene expression in the
hypothalamus has been studied for over three decades,
ever since the cloning of the gene itself [5], the molecu-
lar details of the signaling and transcriptional mecha-
nisms involved have remained elusive. That said, some
evidence suggests that the cAMP/PKA pathway posi-
tively regulates expression of Avp, possibly through the
phosphorylated cAMP responsive element-binding pro-
tein (CREB) [6, 7]. An increase in cAMP and phosphory-
lated CREB was observed in the SON during osmotic
stimulation [7, 8]. Activation of cAMP by forskolin
(FSK; an adenylate cyclase activator) in dissociated hypo-
thalamic primary culture, and treatment of fetal hypo-
thalamic cultures with a protein kinase A activator,
served to increase Avp expression [6, 9]. Moreover the
in vitro analysis of the rat Avp promoter in the human
choriocarcinoma cell line JEG-3 identified two cAMP re-
sponsive element (CRE)-sites (−227/-220 and −123/-116),
and the expression of a dominant negative form of CREB
decreased Avp promoter activity, suggesting that the
CREB protein regulates Avp transcription [10]. However,
the function of CREB as a transcription factor for Avp was
not confirmed in vivo [11]. In addition, a role for the im-
mediate early gene Fos/Jun transcription factor family in
Avp transcription has also been proposed through binding
to an activator protein 1 (AP1) regulatory sequence in the
Avp promoter [12–14].
On the other hand, glucocorticoids, the end product
of hypothalamo-pituitary-adrenal axis, were shown to
negatively regulate the expression of Avp in the hypo-
thalamus as part of a negative-feedback loop. With-
drawal of glucocorticoids by adrenalectomy results in
increased Avp mRNA expression in the PVN [15, 16],
which can be reversed by glucocorticoid replacement
[17]. There is also evidence supporting a role for gluco-
corticoids in the control of water homeostasis. In 2004,
Durlo and colleagues reported increase of plasma cor-
ticosterone concentration, an event well known to occur
in stress conditions, in response to hypervolemia and
hyperosmolarity [18]. Moreover long-term hypoosmolal-
ity has been shown to increase glucocorticoid receptor
expression in vasopressinergic MCNs of the SON, sug-
gesting that glucocorticoids can inhibit AVP synthesis in
response to osmotic cues [19]. In vitro promoter analysis
studies have reported negative effects of glucocorticoid
on Avp promoter activity [10], but the regulatory mecha-
nisms have been unclear.
Recently, we identified the basic leucine zipper tran-
scription factor CREB3L1 (cAMP-responsive element
binding protein 3 like 1; also called OASIS) as a putative
transcriptional regulator of Avp expression in the rat
hypothalamus [20]. CREB3L1, an endoplasmic reticulum
(ER) and Golgi-resident protein, is a transcription factor
in CREB/ATF family. Its structure is similar to ER stress
inducer ATF6 (Activating transcription factor 6) which
contains N-terminal activation, transmembrane and C-
terminal domains. CREB3L1 is activated by regulated
intramembrane proteolysis, resulting in the release of an
N-terminal activating domain that is transported to the
nucleus, where it regulates the transcription of target
genes [21]. Activation of CREB3L1 was shown to be in-
duced by ER stress in many physiological models but the
mechanism of activation in neurons of the hypothalamus
has never been reported.
Interestingly, cAMP was recently shown to activate ex-
pression of Creb3l1 in trophoblast cell line BeWo [22].
Thus in this study, we tested the hypothesis that expres-
sion of CREB3L1, a newly identified transcription factor
of AVP may be regulated through cAMP pathway and
glucocorticoid, the previously proposed regulators of
AVP expression, and the effects of these regulators on
AVP transcription may be mediated through CREB3L1
expression.
Results
Effect of cAMP and glucocorticoid on Creb3l1 expression
To investigate molecular details of the cAMP and gluco-
corticoid effects on Creb3l1 expression, we used the
mouse pituitary AtT20 cell line as a model. The expres-
sion of Creb3l1 mRNA in AtT20 cells was investigated by
qPCR. Treatment with cAMP activator (10 μM forskolin;
FSK) increased Creb3l1 mRNA expression in a time-
dependent manner (Fig. 1a). This increase was main-
tained, although at a reduced level, at the 24 h time point.
Immunoblotting also revealed an increase in CREB3L1
protein abundance following FSK treatment (Fig. 1b). Both
the cleaved form and full length of CREB3L1 are clearly
observed 2 h after FSK treatment, and levels of both in-
creased in a time-dependent manner, in parallel with
mRNA abundance. We also performed immunoblotting
on fractionated cytosolic and nuclear extracts of AtT20
cells treated with FSK for 24 h (Fig. 1c). An increase of
both forms of CREB3L1 was observed in the cytosolic por-
tion of FSK-treated cells, with the cleaved form being ma-
jorly increased in the nuclear fraction. This suggests that
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the amount of CREB3L1 is increased following FSK treat-
ment, and that the full-length protein is subsequently
processed, with the N-terminal active cleavage product be-
ing transported to the cell nucleus.
Next, the effect of glucocorticoid was investigated in
AtT20 cells using a potent glucocorticoid medication,
dexamethasone (DEX). We first characterized the effect
of FSK and/or DEX on AtT20 cells using the expression
of c-Fos, an immediate early gene that requires cAMP
for activation [23], as a marker for cAMP activation
(Fig. 1d). FSK treatment rapidly, but transiently, increased
c-Fos mRNA levels. The maximal induction was reached
at 1 h, with levels returning to baseline by 24 h. DEX
treatment had no effect on basal c-Fos mRNA level but re-
duced the effect of FSK induction. DEX effects on Creb3l1
expression were investigated by qPCR (Fig. 1d). Treatment
with DEX progressively decreased Creb3l1 mRNA expres-
sion under basal conditions. As before (Fig. 1a), FSK treat-
ment increased Creb3l1 transcript abundance, while DEX
attenuated this effect of FSK on Creb3l1 mRNA expres-
sion. CREB3L1 immunoblotting showed an increase of
CREB3L1 following 24 h of FSK treatment. Lower levels
of CREB3L1 were observed following DEX treatment
compared to controls, and the combination of FSK and
DEX reduced CREB3L1 protein levels compared to FSK
treatment alone (Fig. 1e).
Effect of FSK and DEX treatment on Creb3l1 in
organotypic cultures of rat hypothalamus
To investigate the effect of cAMP and glucocorticoid on
Creb3l1 expression in the neurons of hypothalamus, we
investigated the effect of FSK and DEX in the organoty-
pic culture extracted from rat hypothalamus (Fig. 2a).
This model was successfully used to study activation of
Avp by cAMP [24]. Immunofluorescent staining using
an antibody recognizing AVP NP-II confirmed the sur-
vival of AVP neurons in these cultures (Fig 2b). The ef-
fects of FSK and DEX treatments on Creb3l1 expression
in the organotypic cultures were investigated by qPCR.
Cultures were treated with FSK and/or DEX for 4 and
24 h (Fig. 2c). An increase in c-Fos expression was ob-
served at the early time point of treatment (4 h), but not
24 h, after FSK treatment. DEX had no significant effect
on basal level of c-Fos mRNA at both time points; how-
ever it inhibited the effect of FSK-induced c-Fos expres-
sion at the 4 h time point. Creb3l1 expression increased
following FSK treatment at both 4 h and 24 h time
points. Interestingly, DEX treatment alone increased
Fig. 1 cAMP and glucocorticoid regulate Creb3l1 expression. AtT20 cells were used to study regulation of Creb3l1. a–c AtT20 cells were treated with
10 μM FSK or vehicle (DMSO). a Creb3l1 mRNA expression was observed by qPCR at various time points (n = 3; One way ANOVA). b–c Immunoblotting
was performed to examine protein expression level of CREB3L1 in both b total protein extracts and c cytosolic/nuclear extracts. d–e AtT20 cells were
treated with vehicle (DMSO), 10 μM FSK and/or 100nM DEX at various time points. d Effect of glucocorticoid on c-Fos and Creb3l1 expression was
examined by qPCR (n = 3; Two way ANOVA). e Immunoblotting of CREB3L1 was performed at 24 h after treatment. GAPDH was used as an internal
control for immunoblotting. * in B and E indicates non-specific band in immunoblotting. * in D indicate significant from FSK + DEX compared to FSK
group. Scale bar, 20 μm; Error bar, +SEM; *,p < 0.05, **, p < 0.01; ***, p < 0.001; FSK, forskolin; DEX, dexamethasone
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Creb3l1 expression at 24 h, not the 4 h time point, but
inhibited FSK-mediated induction. As expected, FSK
treatment increased hnAvp levels, an effect also inhibited
by DEX. Avp mRNA only increased at the 24 h FSK
treatment, where DEX also inhibited the effect of FSK.
Activation of cAMP pathways modulates Avp transcription
through CREB3L1
We asked if cAMP pathways could activate the Avp pro-
moter in AtT20 cells. AtT20 cells were transfected with
luciferase reporter gene plasmids containing 1 kb of the
rat Avp promoter, and then treated with FSK for 4 h and
24 h (Fig. 3a). Robust increases in luciferase activity were
seen in FSK treated cells compared to vehicle controls at
both time points with a slight decrease of activity at 24 h
compared to 4 h. Effect of DEX on AVP promoter activity
was also investigated (Fig. 3b). Surprisingly we observed
an increase of luciferase activity in response to DEX treat-
ment and a combination of FSK and DEX treatment.
We then tested the hypothesis that the cAMP induced
up-regulation of Avp promoter activity is mediated by
CREB3L1. To do this, Creb3l1-knockdown AtT20 cell
lines were established by transduction of lentivirus con-
taining Creb3l1 shRNA. Control cells expressed a non-
targeting shRNA. The knockdown cells were selected
using puromycin treatment. Successful knockdown was
demonstrated at the Creb3l1 mRNA level by qPCR, and
at the protein level by CREB3L1 immunoblotting (Fig. 3c).
We then examined the effect of FSK treatments on
Creb3l1 mRNA expression in the Creb3l1 knockdown cell
line (Fig. 3d). The results showed that, from its diminished
baseline, Creb3l1 mRNA increased in abundance in re-
sponse of FSK, suggesting that the knockdown cell line is
still able to respond to FSK, but the level of Creb3l1
mRNA expression is massively reduced compared to the
control shRNA cell line. We then transfected the Creb3l1
knockdown AtT20 cells with the luciferase reporter gene
plasmids containing 1 kb of the Avp promoter, and asked
about the response to FSK (Fig. 3e). Whilst FSK treatment
robustly increased luciferase activity driven by the 1 kb
Avp promoters in the control non-targeting shRNA cell
line, knockdown of Creb3l1 substantially diminished this
effect, strongly suggesting that the effect of FSK-induced
activation of the Avp promoter is mediated by Creb3l1.
Fig. 2 Effect of cAMP activation and glucocorticoid in organotypic culture of rat hypothalamus. a Rat hypothalamic explants were cultured on
Millicell membranes. An observation under bright field microscope showed the area of PVN and SCN are intact. b Immunofluorescent staining of
AVP-NPII was performed at day 14 to demonstrate survival of vasopressinergic neurons in the culture. The high magnification image of the area
in the box is shown. c The mRNA expression of hypothalamic explants in response to treatment of 10 μM FSK and/or 100nM DEX for 4 h (n = 5-7) and
24 h (n = 8-15) was examined by qPCR. Scale bar, 100 μm; Error bar + SEM; *, p < 0.05; **, p < 0.01; ***, p < 0.001 (One way ANOVA); FSK, forskolin; DEX,
dexamethasone; PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus. hnAvp, arginine vasopressin heteronuclear RNA
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Creb3l1 expression in the male rat PVN and SON in
response to acute hyperosmotic stress
In vitro study showed that Creb3l1 expression signifi-
cantly increased at 1 h after FSK treatment (Fig.1a). To
examine how quick the activation of Creb3l1 expression
occur in the rat PVN and SON, acute hyperosmotic
stress was induced by intraperitoneal (i.p) injection of
hypertonic saline (1.5 M, 1.5 ml/100 g of body weight).
Hyperosmotic stimulation has previously shown to in-
crease cAMP level in the SON [8]. The expression of
c-Fos mRNA, a marker for neuronal activity which is
also a cAMP-responsive gene, was investigated by qPCR
to demonstrate activation of the PVN and SON in re-
sponse to this stimuli (Fig. 4a). The abundance of the c-
Fos mRNA increased very rapidly (10 min) after injection,
and levels progressively increased until peaking at 60 min.
This was followed by a decline in both PVN and SON. A
higher degree of increase of c-Fos was observed in SON
compared to PVN. At 60 min, the point at which c-Fos
mRNA levels peaked, a statistically significant increase in
Creb3l1 mRNA levels was observed. However, in contrast
with c-Fos, levels did not thereafter decline; rather, the
abundance of Creb3l1 mRNA progressively increased until
the end of the experiment (4 h). A higher level of Creb3l1
mRNA expression was observed in the PVN compared
to the SON (Fig. 4a). Immunostaining of CREB3L1 was
performed in rat PVN and SON following hyperosmotic
stress to investigate CREB3L1 expression and localiza-
tion (Fig. 4b). Compared to the controls injected with
isotonic saline, rats injected i.p. with hypertonic saline
showed a higher level of CREB3L1-like material in both
PVN and SON (4 h after injection). The high magnifica-
tion confocal microscope images showed increased
CREB3L1-like material, together with a change in local-
isation from the perinuclear area in isotonic controls, to
cytoplasmic and nuclear staining in hypertonic injec-
tion, as previously observed following chronic osmotic
stimulation [20].
Glucocorticoids inhibit Creb3l1 and Avp expression in rat
hypothalamus
To investigate glucocorticoid actions on Creb3l1 and Avp
gene expression in vivo, rats were injected with DEX be-
fore injection of isotonic or hypertonic saline (Fig. 5). At
4 h after saline injection, mRNA expression levels were
examined in the PVN and SON. As expected, Creb3l1
mRNA increased in response of hypertonic saline in both
PVN and SON. DEX injection reduced hypertonic-
induced Creb3l1 mRNA expression in both PVN and
SON compared to vehicle controls. Both basal and
hypertonic-stimulated hnAvp expression was diminished
by pretreatment with DEX in PVN and SON. DEX also
decreased hypertonic stimulation of Avp mRNA in PVN
and SON.
Fig. 3 cAMP-activated AVP promoter activity is modulated through
Creb3l1. a-b AtT20 cells were transfected with 1 kb rat Avp promoter
construct. At 24 h after transfection the cells were a treated with
10 μM FSK for 4 and 24 h or b pre-treated with 100nM DEX or DMSO
for 2 h and followed by 4 h treatment of 10 μM FSK or DMSO and
luciferase activity was measured (n = 3). c–e The Creb3l1-knockdown
AtT20 cell line was produced in parallel with a control non-targeting
shRNA cell line by transduction of lentivirus containing Creb3l1 or
control non-targeting shRNA and further selected with puromycin.
c The level of Creb3l1 knockdown was investigated by qPCR and
immunoblotting in the AtT20 shRNA cell lines (n = 3). d The effect of
FSK on Creb3l1 mRNA expression was examined by qPCR in control
non-targeting and Creb3l1 knockdown cell lines (n = 3). e Luciferase
assays were performed in control and Creb3l1-knockdown cell lines
using 1 kb Avp promoter construct driving luciferase reporter gene
(n = 3-4). Error bar + SEM; *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Two
way ANOVA for A, D and E, One way ANOVA for B and independent
sample unpaired Student’s t-tests for C). FSK, forskolin; Con, Control; sh,
shRNA; h, hour; ns, no significant difference
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Discussion
We recently identified CREB3L1 as a transcription factor
capable of regulating Avp gene expression in the rat
hypothalamus in response to the chronic hyperosmotic
stressors of dehydration (1 and 3 days) and salt loading
(1 and 7 days) [20]. However the connection between
this newly identified transcription factor and the previ-
ously proposed mechanism of AVP transcription was
unknown. Here we show that cAMP and glucocorti-
coids, regulators of Avp expression, similarly regulate
Creb3l1 expression. Importantly, we show that CREB3L1
mediates cAMP-induced Avp expression, which is subject
Fig. 4 Creb3l1 expression and localisation in rat PVN and SON in response to acute hyperosmotic stress. Rats were i.p. injected with hypertonic
solution (1.5 M NaCl 1.5 ml/100 g body weight). a The level of c-Fos and Creb3l1 gene expression was examined by qPCR in rat PVN and SON
(n = 5). b Immunofluorescent staining of CREB3L1 (green) and AVP (red) showed early activation of CREB3L1 protein in response of hypertonic
injection. The high magnification images by confocal microscope show the change in localization of CREB3L1 from perinuclear area to cytoplasm
and nucleus in hyperosmotic stress. Scale bar, 70 μm and 10 μm (for confocal). Error bar + SEM; **, p < 0.01; ***, p < 0.001 (One way ANOVA); PVN,
paraventricular nucleus; SON, supraoptic nucleus; AVP, arginine vasopressin
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to glucocorticoid inhibition. Therefore this study pro-
vides the link between CREB3L1 and previously pro-
posed mechanism of AVP transcription.
An increase in cAMP has previously been reported in
response of hyperosmotic stress in the PVN and SON
[8]. There is some evidence showing that Avp expression
is activated through cAMP pathways [6, 10, 25, 26]. To
investigate the control of Creb3l1 expression, and its re-
lationship to Avp transcriptional control, AtT20 cells,
which endogenously express Creb3l1, were used as a
model. The expression of Creb3l1 in these cells responded
robustly to activation of cAMP by FSK treatment, with
mRNA expression increasing after 1 h, similar to that ob-
served following i.p. hypertonic saline administration in
the rat. CREB3L1 protein levels also increased following
FSK treatment, in parallel with the mRNA encoding it.
To confirm an effect of cAMP on Creb3l1 expression
in the hypothalamus, we used hypothalamic organotypic
cultures to study Creb3l1 expression in response to acti-
vation of cAMP pathways. Increase of Avp mRNA in re-
sponse to FSK treatment was previously shown in this
system [25]. The robust increase in Creb3l1 expression
induced by FSK confirmed responsiveness to cAMP
pathways. The increase in hnAvp but not Avp mRNA
after 4 h FSK treatment is consistent with many previous
reports of Avp hnRNA being a sensitive measure of tran-
scriptional activity for this gene [27, 28], without neces-
sarily affecting the large pool of steady-state mature Avp
mRNA. No activation of c-Fos expression at 24 h when
Avp expression is still elevated is consistent with the pre-
viously proposed hypothesis by Arima and colleagues
that c-Fos may be involved but is not essential for the in-
duction of Avp transcription [29].
cAMP activation of AVP transcription is believed to be
mediated by phosphorylation of CREB by PKA [6, 7].
However, a role for phosphorylated CREB in the control
of Avp expression in an in vivo context has not been
substantiated [11]. The shRNA-mediated Creb3l1 knock-
down reduced promoter activity, suggesting that cAMP-
induced Avp transcription is in fact mediated by Creb3l1.
To our knowledge no evidence of a relation between
CREB3L1 and phosphorylated CREB has been reported;
however a study in a trophoblast cell line proposed that
cAMP-induced activation of Creb3l1 is mediated by
p38MAP kinase pathway [22]. The later induction of
Creb3l1 mRNA expression relative to the cAMP indu-
cible immediate early gene c-Fos, both in vitro and in
vivo, certainly suggests the involvement of an intermedi-
ary factor, potentially a transcription factor, though this
remains to be determined. Furthermore, the previous
studies on CREB3L1 also reported that CREB3L1 is acti-
vated by ER stress in several models [30–33]. Although
we previously reported function of CREB3L1 in regula-
tion of ER stress response genes in rat hypothalamus
during hyperosmotic challenge [34], activation of
CREB3L1 expression itself by ER stress has never been
reported in the hypothalamic neurons.
To examine the dynamic changes in gene expression
that govern the hypothalamic response to a hyperosmo-
tic cue, we exploited the acute stimulus of i.p. adminis-
tration of a hypertonic saline solution. As expected,
expression of c-Fos, a cAMP-responsive immediate early
gene, rapidly increased in both PVN and SON, peaking
Fig. 5 Effect of dexamethasone on Creb3l1 expression in the rat PVN
and SON. Rats were injected (i.p.) with either DEX or vehicle. Two
hours after injection, isotonic (IS; 0.15 M NaCl) or hypertonic saline
(HS; 1.5 M NaCl; 1.5 ml/100 g body weight) were administrated (i.p.).
The brains were collected at 4 h after IS/HS injection. qPCR was
performed to examine mRNA expression of Creb3l1 and Avp (n = 6-8).
Error bar + SEM; *, p < 0.05; **, p < 0.01; ***, p < 0.001 (Two-way
ANOVA), +, p < 0.05 (independent sample unpaired Student’s t-tests).
DEX, dexamethasone; PVN, paraventricular nucleus; SON, supraoptic
nucleus; hn, heteronuclear; Avp, arginine vasopressin
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at 1 h and declining thereafter toward basal levels. The
activation of Creb3l1 transcription was slower than that
of c-Fos, but unlike c-Fos, continued to increase from
1 h onwards. We, and others, have reported that hnAvp
expression increases as early as 10 min and reaches a
peak 30 min after hypertonic saline administration
[35, 36]. This means that the increase in hnAvp transcrip-
tion precedes the activation of Creb3l1 mRNA expression
in the PVN and the SON, as observed in the present
study. Such a rapid increase in hnAvp expression implies
that new protein synthesis may not be necessary to
achieve this early response. We previously reported that
CREB3L1 protein expression was most abundant in the
Golgi of MCNs in euhydrated rats [20]. When it is acti-
vated, CREB3L1 is rapidly cleaved by regulated intramem-
brane proteolysis. The released N-terminal domain of the
protein then enters the nucleus to regulate transcription
of target genes [21]. One may speculate that the localisa-
tion of CREB3L1 in the Golgi of euhydrated rats supports
a role for pre-existing CREB3L1 protein in the early acti-
vation of hnAvp transcription. A change in cellular and
subcellular localisation of CREB3L1 was indeed evident
4 h after initiation of hyperosmotic stress (Fig. 4b), similar
to our previous findings at the longer time point of 3 day
dehydration [20]. Moreover, previous study in C6 glioma
cells showed that ER stress inducer dithiothreitol can acti-
vate CREB3L1 at the protein level, while the mRNA level
is unchanged. An activation signal was demonstrated to
increase CREB3L1 stability by inhibiting degradation by
the proteasome system [37]. Such a mechanism may facili-
tate the early function of CREB3L1 in the regulation of
Avp transcription. Further investigation is needed to ad-
dress this issue in the PVN and SON.
Inhibition of Avp expression by glucocorticoids has been
described for many years, although the molecular mecha-
nisms have remained unclear. Putative glucocorticoid re-
sponsive element (GRE) sites were identified in the rat
and bovine Avp promoters (−622/-608 and within −300
to −155, respectively) [38, 39], but were not tested func-
tionally. However, the promoters of many genes that are
negatively regulated by glucocorticoids do not contain
GRE sites, suggesting that the regulatory mechanisms of
glucocorticoids are not only mediated by direct binding of
glucocorticoid receptor to a GRE. The interaction of
glucocorticoid receptor with transcription factors or co-
factors is also believed to be a regulatory mechanism of
glucocorticoids [40]. Here we show that DEX treatment
inhibits both basal and FSK-stimulated Creb3l1 expression
in AtT20 cells. In organotypic cultures, DEX treatment
inhibited FSK-induced Avp expression, in line with previ-
ous reports [24], and also FSK-induced Creb3l1 expres-
sion, similar to our findings in AtT20 cells.
We were surprised that DEX treatment increased Avp
promoter activity in AtT20 cells, disagreeing with previous
studies in hypothalamic neuronal cells and human chorio-
carcinoma cell line JEG-3 that showed DEX treatment in-
hibits Avp promoter activity [10, 41]. AtT20 cells express
glucocorticoid receptors [42] and activation of these re-
ceptors can positively and negatively regulate gene expres-
sion via the direct binding onto DNA or through direct
protein-protein interaction [43]. One possibility is that
DEX may alter other genes that influence Avp promoter
activity in AtT20 cells that do not express Avp. This repre-
sents a limitation of performing promoter studies in
AtT20 cells.
We next tested if peripheral administration of DEX in
the animal could inhibit Avp and/or Creb3l1 stimulation
by hypertonic saline. Indeed, a single injection of DEX sig-
nificantly diminished hypertonic-induced increases in
hnAvp and Creb3l1 expression in both PVN and SON. In
agreement with DEX inhibition of Avp in PVN, with-
drawal of glucocorticoids in the rat by adrenalectomy re-
sults in increased expression of Avp in PCNs, but not
MCNs, and this effect can be reversed by administration
of DEX or corticosterone [15, 17]. It is interesting that we
observed a clear DEX inhibition of Avp expression in the
whole PVN. Studies of glucocorticoid regulation in the
PVN have largely opted for in situ hybridization rather
than qPCR to measure Avp expression specifically in
PCNs [15, 17, 44]. This approach prevents the large pool
of Avp in MCNs masking the changes in gene expression
in the smaller population of PCNs. However, our finding
of DEX inhibition of Avp expression in both PVN and
SON support the concept of DEX modulation of Avp ex-
pression may not only be evident in PCNs, but also in
MCNs consistent with proposed functions of glucocorti-
coids in the control of water homeostasis [45]. It is known
that modulation of excitatory and inhibitory synaptic
transmission by glucocorticoids in the mouse PVN and
SON is lost with conditional deletion of the glucocorticoid
receptor [46]. However, the role of the glucocorticoid re-
ceptor on this DEX-induced regulation of Creb3l1 expres-
sion in MCNs is not known. Therefore, our finding in
AtT20 cells, organotypic cultures, and in vivo study sug-
gest that DEX modulation of Avp expression is perhaps
mediated through DEX-regulation of Creb3l1 expression.
Conclusion
In the long history of the characterisation of the regula-
tory mechanisms controlling expression of Avp, it has
become accepted that the cAMP/PKA pathway is a
major positive regulator for Avp transcription, whilst
glucocorticoids have an inhibitory effect, but the mo-
lecular pathways mediating these effects have remained
largely elusive [40]. Here, we provide evidence that
Creb3l1 is regulated by cAMP and glucocorticoids, and
that this transcription factor may mediate the effects of
these signaling pathways on Avp expression.
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Methods
Animals
Male Sprague–Dawley rats weighing 250–300 g were used
in this study. Rats were housed at a constant temperature
of 22 °C and a relative humidity of 50–60 % (v/v) under a
14:10 h light/dark cycle. The rats were given free access to
food and tap water, unless stated. Animal experiments
were performed between 9 am—2 pm. All experiments
were performed under a Home Office UK licence held
under, and in strict accordance with, the provision of the
UK Animals (Scientific Procedures) Act (1986); they had
also been approved by the University of Bristol Animal
Welfare and Ethical Review Board.
Hypertonic stress experiment
To induce acute hyperosmotic stress, a single i.p. injec-
tion of 1.5 ml/100 g body weight of 1.5 M NaCl solution
was performed. For gene expression study, rats were
randomly allocated into 1 of 6 groups, control, 10 min,
30 min, 1, 2, and 4 hours (h) after administration of
hypertonic saline. To investigate actions of glucocortic-
oid on gene expression in the hypothalamus, rats were
injected i.p. with 0.5 ml 0.15 M NaCl (vehicle) or 0.5 ml
of 1 mg/kg body weight dexamethasone (DEX; Sigma
D2915) 2 h before Isotonic (0.15 M NaCl solution;
1.5 ml/100 g body weight) or hypertonic saline injection.
After injection of hypertonic or isotonic saline rats were
placed back in their home cages for 4 h, and water, but
not food, was removed for the duration of the experi-
ment. For RNA analyses, rats were killed by striking of
the cranium, followed by decapitation, using a guillotine
(Harvard Apparatus). Brains were removed and frozen
on dry ice before being stored at −80 °C. For immuno-
fluorescent study, rats were i.p. injected with hypertonic
saline for 4 h. Isotonic saline solution was injected for
the control group.
Organotypic culture of rat hypothalamus
Organotypic cultures were performed following the proto-
col previously described [47]. Sprague–Dawley pups (P5-
P7) were purchased from Harlan Laboratories (UK). Pups
were decapitated using scissors, and brains were removed
and incubated in cold-Hank’s solution for 5 min, and then
dissected using the optic chiasm as a landmark to produce
a hypothalamic block. The block was placed onto a
Mcllwain Tissue Chopper and 400 μm sections containing
the PVN were cut then transferred to ice-cold Hank’s so-
lution and incubated for 1 h before being placed onto a
Millicell Cell Culture Insert (30 mm, hydrophilic PTFE,
0.4 μm; Millipore PICM03050) in a 6-well tissue culture
plate with 1.1 ml of culture medium. The culture sections
were incubated at 37 °C, 5 % (v/v) CO2 for 14 days before
performing an experiment. The culture medium was re-
placed with fresh media every 2 days, and 4 days before
the experiment the medium was replaced with serum-free
medium. For treatments, culture medium was replaced
with serum-free medium containing 10 μM FSK (Sigma)
and/or 100nM DEX. At appropriate time points, the
membrane was frozen on dry ice, and then the PVN was
punched out using a 1 mm diameter micropunch (Fine
Scientific Tools). The punched tissue was dispersed into a
1.5 ml tube for RNA extraction using Qiazol Reagent with
the Qiagen RNeasy kit as described below.
Cells and treatments
AtT20/D16v-F2 cells (Sigma; 94050406) were cultured in
DMEM (Sigma; D6546) supplemented with 10 % (v/v)
heat-inactivated fetal bovine serum (Gibco), 2 mM L-glu-
tamine and 100 unit/ml of penicillin-streptomycin. Cells
were incubated at 37 °C in a humidified incubator with
5 % (v/v) CO2. For chemical treatments, cells were seeded
onto tissue culture plates to 60–70 % confluence. After
18-24 h, the culture medium was replaced with medium
containing 10 μM FSK (Sigma) and/or 100nM DEX.
To produce a Creb3l1 knockdown cell line, AtT20 cells
were transduced with a lentivirus containing shRNA tar-
geting mouse Creb3l1. The Creb3l1 shRNA sequence
(CGGCTCAATGACTGTGAAAGA) was obtained from
the RNAi consortium shRNA library. Sense and antisense
oligonucleotides for shRNAs were synthesised (European
MWG Operon) and cloned into lentiviral transfer vector
pLKO.1 puro according to manufacturer’s guidelines
(pLKO.1 puro was a gift from Bob Weinberg, Addgene
plasmid 8453). A non-targeting shRNA sequence (ATC
ATGTTAGGCGTACGGACT) was used as a control.
Virus particles were produced as previously described
[20]. Twenty four hours after transduction, puromycin
(2 μg/ml, Life technologies) was added to cell culture
medium. The cells were cultured in presence of puro-
mycin for two weeks before use in experiments. The level
of knockdown was confirmed by quantitative PCR (qPCR)
and immunoblotting of CREB3L1 (see below).
RNA extraction and cDNA synthesis
Frozen brains were sliced into 60 μm coronal sections in
a cryostat. Sections were mounted on glass slides and
stained with 0.1 % (w/v) toludine blue/70 % ethanol then
visualised on a light microscope until brain nuclei were
visible, then PVN and SON samples were collected using
a 1 mm micropunch. The optic chiasm (SON), or neu-
rons staining at the PVN location lateral to the third
ventricle (PVN), were used as a reference. PVN and
SON samples were then dispensed into 1.5 ml tubes and
kept on dry ice within the cryostat. Total RNA was ex-
tracted from punched samples by combining Qiazol Re-
agent with Qiagens RNeasy kit protocols (Qiagen). The
punched samples were removed from dry ice and rapidly
resuspended, by vortexing, in 1 ml Qiazol reagent.
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Following Qiazol phase separation with chloroform,
350 μl of the upper aqueous phase was removed, mixed
with 350 μl 70 % (v/v) ethanol and applied to RNeasy col-
umns. The remaining steps were performed as recom-
mended by the manufacturer. For cDNA synthesis, 200 ng
of total RNA was reverse transcribed using the Quantitect
reverse transcription kit (Qiagen).
For in vitro studies, the culture medium was removed
and the cells were lysed in 350 μl Qiazol Reagent (Qiagen).
The lysate was mixed with 350 μl absolute ethanol and
added directly into the Direct-zol™ RNA MiniPrep col-
umns (Zymo research; R2052) and extraction continued
following the manufacturer’s protocol. For cDNA synthe-
sis, 500 ng of total RNA was reverse transcribed using the
Quantitect reverse transcription kit (Qiagen).
Real-time quantitative PCR analysis
Primers for rat Creb3l1 (5’-GAGACCTGGCCAGAGG
ATAC-3’ and 5’-GTCAGTGAGCAAGAGAACGC-3’),
rat Avp mRNA (5’-TGCCTGCTACTTCCAGAACTGC-
3’ and 5’-AGGGGAGACACTGTCTCAGCTC-3’), rat
Avp heteronuclear RNA (hnAvp) (5’-GAGGCAAGAG
GGCCACATC-3’ and 5’-CTCTCCTAGCCCATGACCC
TT-3’), rat c-Fos (5’-AGCATGGGCTCCCCTGTCA-3’
and 5’-GAGACCAGAGTGGGCTGCA-3’), rat Rpl19
(5’-GCGTCTGCAGCCATGAGTA and 5’-TGGCATTG
GCGATTTCGTTG-3’), mouse c-Fos (5’-TCCCCAAAC
TTCGACCATGA-3’ and 5’-GGCTGGGGAATGGTAG
TAGG-3’), mouse Creb3l1 (5’-ACAAACTGCAGGGGA
CATCA-3’ and 5’-GAGCTTGGTGGGGATAGGG-3’)
and mouse Gapdh (5’-CAACTCCCACTCTTCCACCT-
3’ and 5’-CTTGCTCAGTGTCCTTGCTG-3’) were syn-
thesised by European MWG Operon. The optimisation
and validation of primers was performed using standard
ABI protocols. The cDNA from reverse transcriptase re-
action was used as a template for subsequent PCRs,
which were carried out in duplicate. Quantitative PCR
was conducted in 12.5 μl reaction volumes using SYBR
green master mix buffer (Roche) using an ABI StepOne-
Plus real time PCR system. For relative quantification of
gene expression the 2-ΔΔCT method was employed [48].
The internal control gene used for these analyses were
the housekeeping genes Rpl19 and Gapdh.
Immunofluorescence
Rats were deeply anesthetised with sodium pentobarbit-
one (100 mg/kg i.p.) and transcardially perfused with
0.1 M phosphate buffered saline (PBS, pH 7.4) followed
by 4 % (w/v) paraformaldehyde (PFA) in PBS. Brains
were removed and post-fixed overnight in 4 % (w/v) PFA
followed by 30 % (w/v) sucrose prepared in PBS. Coronal
sections (40 μm) of the forebrain were cut on a cryostat
and washed in PBS three times. Sections then were
blocked in 5 % (v/v) horse serum prepared in PBS with
0.25 % (v/v) TritonX-100 (PBST) for 30 min and then
incubated with goat anti-N-terminal CREB3L1 antibody
(1:250; R&D systems, AF4080) and mouse monoclonal
antibody recognising AVP neurophysin-II (NP-II, PS41;
1:200) [49] prepared in 1 % horse serum/PBST at 4 °C
for 48 h. The sections were washed three times in PBS
for 5 min and incubated with 1:500 dilution of anti-goat
IgG-biotinylated secondary antibody in 1 % horse serum/
PBST for 1 h at room temperature. Sections were washed
three times for 5 min with PBS and incubated for 1 h with
secondary antibodies conjugated with fluorophore (1:500
in 1 % horse serum/PBST; Alexa Fluor 488 streptavidin-
conjugated and Alexa Fluor 594 donkey anti-mouse IgG
(Invitrogen)). After three washes with PBS, sections were
mounted onto glass slides with 0.5 % (w/v) gelatin, and
sealed with VectorShields hard mounting media (Vector
Laboratories Ltd.). For organotypic culture, the tissues on
Millicell Cell Culture Insert were fixed with 4 % (w/v) PFA
in PBS for 20 min and washed three times with PBS for
5 min. Tissues then were blocked and incubated with anti-
bodies as described above. Images were captured on fluor-
escent microscope and confocal microscope (Leica). The
specificity of anti-N-terminal CREB3L1 antibody in im-
munofluorescent staining was previously validated [20].
Protein extraction and immunoblotting
Cells were washed twice with cold PBS pH 7.4 (Gibco;
10010–015), and harvested by scraping into RIPA buffer
(1 % (w/v) IGEPAL CA-630 (Sigma I3021), 0.5 % (w/v)
sodium deoxycholate, and 0.1 % (w/v) sodium dodecyl
sulfate (SDS) prepared in PBS) supplemented with
1 mM PMSF and Protease Inhibitor Cocktail (Sigma;
P8340). The lysate was incubated on ice for 15 min with
vortexing every 5 min, followed by centrifugation at
10,000 × g for 10 min. Supernatants were collected and
kept at −80 °C. For cytosolic and nuclear protein extrac-
tion, cells were harvested in 500 μl hypotonic buffer so-
lution (for 5 × 106 cells ; 20 mM Tris–HCl, pH 7.4,
10 mM NaCl, 3 mM MgCl2) supplemented with 1 mM
PMSF and Protease Inhibitor Cocktail, then moved to
1.5 ml tube and gently resuspended by pipetting before
being incubated on ice for 15 min. 25 μl of 10 % IGEPAL
CA-630 was added to the lysate and vortexed for 10 sec-
onds. The lysate was centrifuged at 1,000 × g at 4 °C for
10 min, and the supernatant was collected as the cyto-
solic protein. The pellet was resuspended in 50 μl of Cell
Extraction Buffer (100 mM Tris, pH 7.4, 2 mM Na3VO4,
100 mM NaCl, 1 % (v/v) Triton X-100, 1 mM EDTA,
10 % (v/v) glycerol, 1 mM EGTA, 0.1 % (w/v) SDS,
1 mM NaF, 0.5 % (w/v) deoxycholate, 20 mM Na4P2O7,
supplemented with 1 mM PMSF and Protease Inhibitor
Cocktail) and incubated on ice for 30 min with vortexing
at 10 min intervals. The lysate was centrifuged at
14,000 × g at 4 °C for 30 min, and the supernatant was
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collected as the nuclear fraction. Protein concentrations
were determined using the Bradford assay (Bio-Rad).
For immunoblotting, proteins were separated by SDS-
PAGE and transferred to 0.45 μm PVDF membranes
(Millipore). The membranes were blocked with 5 % (w/v)
skimmed-milk prepared in Tris-buffered saline-0.05 %
Tween 20 (TBS-T) for 1 h at room temperature, followed
by incubation with primary antibody diluted in 3 % (w/v)
skimmed-milk in TBS-T at 4 °C overnight. This was
followed by incubation with appropriate secondary anti-
body conjugated with horseradish peroxidase (HRP) at
room temperature for 1 h. Signal was visualised using high
sensitivity WESTAR EtaC or WESTAR SuperNova ex-
treme sensitivity HRP Detection Substrate (Cyanagen).
Primary antibodies used: a goat polyclonal anti-N-terminal
CREB3L1 (1:1,000; R&D systems, AF4080) and a mouse
polyclonal anti-GAPDH (1:20,000; Santa Cruz, sc-32233).
Secondary antibodies used: rabbit anti-Goat IgG (whole
molecule)–peroxidase antibody (Sigma: A5420) and
rabbit anti-Mouse IgG (whole molecule)–Peroxidase
antibody (Sigma: A9044). The specificity of anti-N-
terminal CREB3L1 antibody in immunoblot assay was
previously validated [20].
Luciferase assays
For luciferase assays, we used 1 kb rat Avp promoter lu-
ciferase reporter construct cloned into pGL3 vector
(Promega) as described previously [20]. AtT20 cells were
seeded onto 12-well tissue culture plates. Next day, plas-
mids (1 μg pGL3-Avp promoter and 0.1 μg pRL-TK vector/
well) were transfected into cells using lipofectamine LTX
with Plus transfection reagent (Life Technologies) following
the manufacturer’s protocol. For chemical treatments, the
culture medium was replaced with fresh medium contain-
ing 10 μM FSK or DMSO (vehicle) 24 h after transfection.
For DEX treatment, the cells were pre-treated with DMSO
or 100nM DEX for 2 h followed by treatment with 10 μM
FSK or DMSO for 4 h. Cells were harvested at appropriate
time points. Luciferase assays were performed using the
Promega Dual-Luciferase® Reporter Assay. Luciferase ac-
tivity was measured in triplicate using a Lumat LB 9507
Luminometer (Berthold Technologies).
Statistical analysis
All data are expressed as the mean + SEM. Statistical dif-
ferences between experimental groups were evaluated
using independent sample unpaired Student’s t-tests or
One-way ANOVA with Tukey post test (for comparison
of more than 2 groups). Two-way ANOVA with Bonfer-
onni post hoc test was used to determine interactions
between two independent variables on the dependent
variable. If Bartlett’s test for equal variances has p < 0.01
in One-way ANOVA, data was log transformed before
analysis. p < 0.05 was considered significant.
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